Savaysa

Chemical Nameedoxaban
Dosage FormTablet (oral; 15 mg, 30 mg, 60 mg)
Drug ClassInhibitors
SystemBlood
CompanyDaiichi Sankyo Inc.
Approval Year2015

Indication

  • To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Savaysa (edoxaban) Prescribing Information2019Daiichi Sankyo, Inc., Basking Ridge, NJ